Announcement • Jun 09
Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million. Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,083,333
Price\Range: AUD 0.024
Transaction Features: Subsequent Direct Listing Announcement • Apr 21
Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 3.36 million. Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 3.36 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,666,667
Price\Range: AUD 0.024
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 133,333,333
Price\Range: AUD 0.024
Transaction Features: Subsequent Direct Listing New Risk • Apr 02
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.5m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.4m free cash flow). Shareholders have been substantially diluted in the past year (212% increase in shares outstanding). Revenue is less than US$1m (AU$100k revenue, or US$69k). Market cap is less than US$10m (AU$14.5m market cap, or US$9.92m). Reported Earnings • Mar 04
First half 2026 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2025) First half 2026 results: AU$0.011 loss per share (in line with 1H 2025). Net loss: AU$3.02m (loss widened 99% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. New Risk • Feb 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.4m free cash flow). Shareholders have been substantially diluted in the past year (212% increase in shares outstanding). Revenue is less than US$1m (AU$100k revenue, or US$71k). Minor Risk Market cap is less than US$100m (AU$20.9m market cap, or US$14.9m). Board Change • Feb 04
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. 1 highly experienced director. 2 independent directors (3 non-independent directors). Member of Scientific Advisory Board Allen Ebens is the most experienced director on the board, commencing their role in 2016. Independent Non-Executive Chairman Peter Christie was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Jan 29
Patrys Limited (ASX:PAB) completed the acquisition of Reliis Ltd. Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd on November 26, 2025. The consideration consists of 110 million common equity of Patrys Limited to be issued for common equity and 25 million common equity of Patrys Limited to be issued for convertible debt of Reliis Ltd. Patrys Limited will pay an earnout payment 40 million Class A Performance Rights and 30 million Class B Performance Rights contingent upon the first subject being dosed in a Phase 1 Clinical Study and successful IND approval by a regulatory body, respectively.
The transaction is subject to approval by regulatory board / committee and approval of offer by shareholders of Patrys Limited. As of January 19, 2026 acquirer shareholders have approved this transaction.
Patrys Limited (ASX:PAB) completed the acquisition of Reliis Ltd on January 28, 2026.
As of January 27, 2026 legal, technical and financial due diligence, all remaining conditions precedent under the Share Sale Agreement have been satisfied (or waived) and all transaction documents have now been duly executed. Announcement • Nov 27
Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd. Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd on November 26, 2025. The consideration consists of 110 million common equity of Patrys Limited to be issued for common equity and 25 million common equity of Patrys Limited to be issued for convertible debt of Reliis Ltd. Patrys Limited will pay an earnout payment 40 million Class A Performance Rights and 30 million Class B Performance Rights contingent upon the first subject being dosed in a Phase 1 Clinical Study and successful IND approval by a regulatory body, respectively.
The transaction is subject to approval by regulatory board / committee and approval of offer by shareholders of Patrys Limited. Announcement • Nov 11
Patrys Limited Announces Management Changes, Effective 10 November 2025 Patrys Limited announced that Dr. James Campbell has tendered his resignation as a Non-Executive Director of the Company, effective 10 November 2025. Dr. Campbell's tenure with the company commenced in November 2014, where he was originally a Non-Executive Director from 12 November 2014, then appointed as Managing Director and Chief Executive Officer (CEO) of the Company for the period 13 April 2015 to 30 June 2025. Dr. Campbell's CEO role was made redundant on 1 July 2025. Since 1 July 2025 Dr Campbell has been a Non-Executive Director. The company also announced the appointment of Mr. Brian Leedman as a Non-Executive Director, effective 10 November 2025. Mr. Brian Leedman is a seasoned biotechnology executive and company director with more than 20 years of experience in corporate strategy, investor relations, and capital markets within the life sciences sector. He is the founder and former director of ResApp Health Ltd, which was acquired by Pfizer Inc. in 2022, and has held board roles across a range of ASX-listed biotechnology companies, including Neuroscientific Biopharmaceuticals, Neurotech International, Alcidion Corporation, Oncosil and others. Mr. Leedman is currently a Non-Executive Chairman of Blinklab Ltd. and has extensive experience guiding emerging biomedical companies from early research through to clinical development and commercialisation. He is well recognised in the Australian biotech community for his leadership in capital raising, corporate governance, and building investor awareness for innovative medical technologies. Mr. Leedman holds a Bachelor of Economics and an MBA from the University of Western Australia. His deep understanding of the biotech industry and proven record of creating shareholder value will provide valuable strategic insight to Patrys as it advances its deoxymab platform through preclinical and clinical development. The Company also advises that Mr. Johnathon Busing and Mr. Kieran Witt have been appointed as Joint Company Secretaries of the Company, with effect from 10 November 2025. Mr. Busing is a Chartered Accountant and the founder of Eleven Corporate, a Perth-based corporate services firm. He has extensive experience in accounting, corporate advisory, governance and ASX compliance, and currently acts as Company Secretary and Chief Financial Officer for a number of ASX- listed companies. Mr. Witt is a Chartered Accountant with extensive experience as a consultant advising ASX listed companies on capital raisings, mergers and acquisitions, statutory accounting requirements and corporate compliance. Currently, he also serves as the Company Secretary for several other ASX-listed companies, where he oversees compliance with corporate governance requirements and regulatory obligations. He is a member of Chartered Accountants Australia and New Zealand and holds a Bachelor of Commerce (Accounting). Mr. Busing and Mr. Witt will be the persons responsible for communication with the ASX in relation to Listing Rule matters under Listing Rule 12.6. As part of this change, Mr. Stefan Ross will step down from his role as Company Secretary, effective 10 November 2025. Announcement • Sep 08
Patrys Limited, Annual General Meeting, Oct 09, 2025 Patrys Limited, Annual General Meeting, Oct 09, 2025. Recent Insider Transactions • Sep 06
Non-Executive Director recently bought AU$200k worth of stock On the 4th of September, Anton Uvarov bought around 200m shares on-market at roughly AU$0.001 per share. This transaction increased Anton's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. New Risk • Sep 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 78% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (75% average weekly change). Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Revenue is less than US$1m (AU$829k revenue, or US$544k). Market cap is less than US$10m (AU$4.58m market cap, or US$3.01m). Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2024) Full year 2025 results: AU$0.001 loss per share (in line with FY 2024). Revenue: AU$828.5k (down 41% from FY 2024). Net loss: AU$3.01m (loss narrowed 15% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Announcement • Jul 23
Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.774357 million. Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.774357 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,774,357,402
Price\Range: AUD 0.001
Discount Per Security: AUD 0.00006
Transaction Features: Rights Offering Announcement • Jun 10
Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.358363 million. Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.358363 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 308,362,535
Price\Range: AUD 0.001
Discount Per Security: AUD 0.00006
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,000,000
Price\Range: AUD 0.001
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Reported Earnings • Feb 25
First half 2025 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2024) First half 2025 results: AU$0.001 loss per share (in line with 1H 2024). Revenue: AU$730.5k (up 9.1% from 1H 2024). Net loss: AU$1.52m (loss narrowed 22% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Announcement • Oct 21
Patrys Limited, Annual General Meeting, Nov 22, 2024 Patrys Limited, Annual General Meeting, Nov 22, 2024. Reported Earnings • Aug 24
Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2023) Full year 2024 results: AU$0.002 loss per share (improved from AU$0.003 loss in FY 2023). Revenue: AU$1.39m (down 51% from FY 2023). Net loss: AU$3.54m (loss narrowed 50% from FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. New Risk • May 16
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.61m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 32% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.61m). Minor Risk Revenue is less than US$5m (AU$1.7m revenue, or US$1.1m). New Risk • Apr 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 32% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$1.7m revenue, or US$1.1m). Market cap is less than US$100m (AU$16.4m market cap, or US$10.8m). New Risk • Feb 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.38m). Minor Risk Revenue is less than US$5m (AU$2.9m revenue, or US$1.9m). New Risk • Nov 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.51m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.51m). Minor Risk Revenue is less than US$5m (AU$2.9m revenue, or US$1.9m). Announcement • Sep 15
Patrys Limited Announces Retirement of Suzy Jones as Director Patrys Limited announced that Ms. Suzy Jones will be retiring as a Director of the company effective from close of business on 15 September 2023. Ms. Jones joined the Patrys Board in 2011 and has played a pivotal role in the Company's evolution over the last decade. Her corporate strategy, drug development and business development guidance helped Patrys gain access to novel technologies and expand its portfolio. Ms Jones also leveraged her global network to attract industry experts to support Patrys' mission. Ms. Jones is Founder and Managing Partner of DNA Ink LLC, a life sciences advisory firm in San Francisco and prior to starting her own firm, spent 20 years at Genentech where she served in roles in immunology research, product development and business development. Ms. Jones' departure aligns with the Company's previously noted vision to refresh its Board of Directors in keeping with good governance practices. Ms. Jones has on-going obligations as co-founder of an antibody drug conjugate company and consultant CBO to her DNA Ink clients. Patrys has now commenced searching for a new Non-Executive Director to help contribute to its next phase of growth as it becomes a clinical-stage therapeutic development company. Reported Earnings • Aug 30
Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2022) Full year 2023 results: AU$0.003 loss per share (in line with FY 2022). Revenue: AU$2.85m (down 14% from FY 2022). Net loss: AU$7.06m (loss widened 4.1% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year. Announcement • Aug 28
Patrys Limited, Annual General Meeting, Nov 15, 2023 Patrys Limited, Annual General Meeting, Nov 15, 2023. New Risk • Aug 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.9m free cash flow). Earnings have declined by 36% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$3.5m revenue, or US$2.2m). Market cap is less than US$100m (AU$18.5m market cap, or US$11.9m). Reported Earnings • Feb 25
First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in 1H 2022) First half 2023 results: AU$0.002 loss per share (in line with 1H 2022). Revenue: AU$1.83m (up 10% from 1H 2022). Net loss: AU$3.89m (loss narrowed 14% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Announcement • Nov 16
Patrys Limited Appoints Charmaine Gittleson as the Chairman of the Board of Directors, Effective November 16, 2022 Patrys Limited announced the appointment of Dr. Charmaine Gittleson as the Chairman of the Board of Directors, effective from the conclusion of the Company's Annual General Meeting later on November 16, 2022. Dr. Gittleson is the former Chief Medical Officer of CSL Limited with more than 20 years of experience in pharmaceutical development in Australia and the USA. Dr. Gittleson's expertise spans many aspects of the pharmaceutical industry, from drug development and clinical research through to strategic planning and executive management. Dr. Gittleson has been involved in drug development programs across a wide range of different therapeutic areas, and has successfully worked with regulators in key markets such as the US, EU, Asia Pacific, Japan and South America. Dr. Gittleson is currently the Chair of Antisense Therapeutics Limited where she has been actively involved in strategy development, capital raising and Board renewal. Dr. Gittleson is joining Patrys at an exciting time in the Company's evolution as it completes the last remaining stages of preclinical development for PAT-DX1 in preparation for its first clinical trial, which is scheduled to commence in the second half of 2023. In parallel, Patrys is in the process of establishing a commercial-scale production process for its second deoxymab, PAT-DX3, which is a full-sized IgG antibody capable of delivering therapeutic payloads into the nucleus of cancer cells. The Company also advises that, as previously foreshadowed, Mr. Stefan Ross will step down from the Board of Directors at the close of business on November 16, 2022, now that a permanent Chairman has been found. Stefan will remain as Company Secretary, maintaining his seven year affiliation with the Company. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director & Company Secretary Stefan Ross was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Oct 17
Patrys Limited Announces New Preclinical Data for its Full-Sized IgG Antibody, Pat-DX3 Patrys Limited announced new preclinical data for its full-sized IgG antibody, PAT-DX3. Results from a new study support the potential to use deoxymabs to deliver small molecule therapeutics and gene editing technologies across the blood-brain barrier to treat various neurological targets and conditions. This study was conducted by a leading global contract research organisation which radioactively labelled both PAT-DX3 and a control antibody to monitor their relative uptake into various tissues over the course of four days. The study's goal was to establish the distribution of PAT-DX3 in a range of different tissues to assist in the selection of future targets and payloads for future potential antibody drug conjugate (ADC) development programs. The study found that the uptake into the brain (per cubic centimetre) of PAT-DX3 was 34 fold higher than that of a control antibody soon after injection, and this persisted for the duration of the study period. This compares favourably to antibodies that have been specifically engineered for enhanced blood-brain barrier crossing that have reported brain uptake values 23 fold higher than control antibodies1. The area under the curve (AUC) of PAT-DX3, a measurement of overall drug exposure, was approximately seven times greater for PAT-DX3 than it was for the control antibody in this study, with significant concentrations of antibody still in the brain after four days. The ability of PAT-DX3 to cross the blood-brain barrier is consistent with current data which indicates that Patrys' deoxymabs enter cells using the ENT2 transporter protein; a protein which is highly expressed in the neural vasculature. Elevated levels of PAT-DX3 were found in brain tissue but not in a range of other tissues including the lung, the liver and the thyroid adding further support to this proposed mechanism for crossing the blood-brain barrier. Announcement • Oct 07
Patrys Limited, Melbourne Ordinary Shares to Be Deleted from OTC Equity Patrys Limited, Melbourne Ordinary Shares will be deleted from OTC Equity effective from October 07, 2022 due to Inactive Security. Reported Earnings • Aug 31
Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2021) Full year 2022 results: AU$0.003 loss per share (vs AU$0.003 loss in FY 2021). Revenue: AU$3.33m (up 149% from FY 2021). Net loss: AU$6.78m (loss widened 67% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • Aug 30
Patrys Limited Announces Update on PAT-DX1 From Engineering Run Meets all Specification Tests Patrys Limited announced its Contract Development Manufacturing Organization (CDMO) has successfully completed specification testing of PAT-DX1 drug substance produced in the recently-completed engineering run. As anticipated, the GMP material produced has passed all specification requirements and can now be used to complete remaining pre- clinical toxicology studies in preparation for a phase 1 clinical trial of PAT-DX1 that is planned to commence in H2 CY2023. Specification, or batch release, testing is a necessary requirement to ensure high quality pharmaceuticals are used in GMP and clinical studies. A wide range of analytical tests are conducted to analyse the physical characteristics of the drug substance and to ensure that the activity and purity of the drug material fall within pre-defined tolerance levels. The PAT-DX1 drug material has also undergone microbiological and chemical testing to verify the absence of contaminants. This GMP PAT-DX1 drug material will be used to complete the two remaining animal toxicology studies that are required before first-in-man studies can be initiated. Patrys has already successfully completed animal toxicology studies using non-GLP PAT-DX1 drug material and these showed that it is safe and well-tolerated. No mortalities or antibody-related changes in body weight, hematology or clinical chemistry were observed in these studies which were conducted in two different animal species (rodents and primates). These data have been used to inform the design of GLP toxicology studies for PAT-DX1 which are scheduled to commence in Fourth Quarter CY2022. Announcement • Aug 11
Patrys Limited Announces New Pre-Clinical Data for Its Lead Asset, Pat-Dx1 Patrys Limited announced new pre-clinical data for its lead asset, PAT-DX1. Results from a new study provide strong support for the continued development of PAT-DX1 to improve patient outcomes in high grade glioma (HGG), a fast growing and clinically challenging form of brain cancer. The study was conducted in the laboratory of Professor Terrence Johns of the Telethon Kids Cancer Centre. The study showed that combining a therapeutic dose of standard radiation therapy (red bar) with 25mg/kg dose of PAT-DX1 (blue bar) increased median survival by 12 days (p<0.0002) compared to radiation treatment alone (n=10 per group). Additionally, even at a lower dose than previously used PAT-DX1 showed significant activity as a single agent, confirming previous studies in a range of brain cancers models. HGG is the most common and deadly type of brain cancer, affecting both adults and children. Adult patients have a 5-year survival rate of 10% with standard therapy (surgical resection, radiation and chemotherapy). In children HGG is a rapid and universally lethal disease. HGG is called "high-grade" because the tumors are fast-growing and spread quickly through brain tissue making them very difficult to treat. Announcement • Jul 04
Patrys Limited Announces Successful Completion of Pat-Dx1 Engineering Run Patrys Limited announce that its Contract Development Manufacturing Organisation has successfully completed a second engineering run which used an updated purification process to produce large scale quantities of clinical grade PAT-DX1. Subject to meeting specification, the manufactured PAT-DX1 antibody from this engineering run will provide sufficient PAT-DX1 for Patrys to complete the remaining pre-clinical toxicology studies in preparation for a proposed phase 1 clinical trial of PAT-DX1 in second half of CY2023. The engineering run consisted of two phases; a fermentation phase, in which cells were grown in culture to produce PAT-DX1, followed by a purification phase, in which the PAT-DX1 produced during the fermentation process was isolated and purified. As announced by Patrys on 24 January 2022, the first engineering run for PAT-DX1 was unsuccessful due to low recoveries of drug product during the purification phase. Patrys and its CDMO subsequently developed a modified purification process that was used in this second engineering run. The initial yield from this commercial scale run exceeds what the Company was expecting based on previous, smaller-scale pilot runs. In the coming weeks, the PAT-DX1 antibody product from this engineering run will be tested to ensure that it meets specification. As PAT-DX1 from all prior manufacturing runs to date has met specification, Patrys expects to complete pre-clinical GLP toxicology studies as planned from Fourth Quarter CY2022 to Second Quarter CY2023. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Scientific Advisory Board Peter Ordentlich was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions Derivative • Sep 08
MD, CEO & Executive Director exercised options to buy AU$360k worth of stock. On the 2nd of September, James Campbell exercised options to buy 9m shares at a strike price of around AU$0.0072, costing a total of AU$65k. This transaction amounted to 107% of their direct individual holding at the time of the trade. Since December 2020, James has owned 8.43m shares directly. Company insiders have collectively bought AU$108k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Aug 26
Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2020) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$1.34m (up 73% from FY 2020). Net loss: AU$4.06m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Announcement • Aug 05
Patrys Limited Provides This Interim Update on Its PAT-DX1 Clinical Trial Program Patrys Limited provided this interim update on its PAT-DX1 clinical trial program. As announced in February 2021, Patrys has selected a stable, high-yielding cell line suitable for the commercial production of clinical-grade PAT-DX1. Using this cell line, Patrys' commercial contract manufacturer has prepared production and purification processes for PAT-DX1 at its facility. Planning for this campaign commenced over 12 months ago and included ordering the required materials 6 months in advance of use. Patrys has now been advised by its manufacturer that there are anticipated delays in procuring certain key components required for the fermentation media used for PAT-DX1 production. These pending delays are entirely due to the impact of the COVID-19 pandemic on global reagent production and supply chains and are outside the control of either Patrys or its contract manufacturer. The proprietary
nature of these key reagents means that the Company is not able to source materials from alternative suppliers. As a result, the engineering run for PAT-DX1 is now anticipated to be delayed until Fourth Quarter 2021. The anticipated deferred commencement of the engineering run for PAT-DX1 means the start of the GMP toxicology studies for PAT-DX1 has been rescheduled to First Quarter CY2022, pending the availability of GMP grade PAT-DX1. On this revised timeline, Patrys expects it will now submit a Human Research Ethics Application (HREA) for the phase 1 clinical trial in H2 CY2022. Announcement • Jul 14
Patrys Limited Announces Full Size Deoxymab PAT-DX3 Able to Cross the Blood Brain Barrier Patrys Limited announced new data from non-clinical studies have confirmed its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross the blood-brain barrier (BBB) in an animal model of primary brain cancer (glioblastoma multiforme, GBM). Previous studies conducted by Patrys and its collaborators have shown that PAT-DX1, a deoxymab antibody fragment, is able to cross the BBB in animal models of both primary and secondary brain cancer where it reduces tumour volume and increases survival. This is the first time it has been shown that the full size deoxymab, PAT-DX3, is also able to cross the BBB. Prior to this data, it had not been established whether the larger size of PAT-DX3 would limit its ability to cross the BBB. Patrys intends to follow up this discovery with studies to compare the effects of both PAT-DX3 and PAT-DX1 on tumour reduction and survival in a range of primary and secondary brain cancer models. In addition to its potential as a therapeutic agent in its own right, PAT-DX3 is also currently being tested as a targeting antibody for antibody drug conjugates (ADCs) to allow the delivery of various therapeutic payloads. The fact that PAT-DX3 can transit the BBB will be of particular relevance if it can successfully be conjugated to small molecule drugs. Announcement • Jun 16
Patrys Limited Announces the Publication of New Preclinical Data for Its Deoxymab Antibody PAT-DX1 Patrys Limited announced the publication of new preclinical data for its deoxymab antibody PAT-DX1. This data, from studies conducted in three different animal models, further demonstrates the unique ability of Patrys' PAT-DX1 antibody to cross the blood-brain barrier (BBB) and significantly inhibit the growth of both primary and secondary cancers in the brain. The publication, entitled "ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody", has been published in the leading, peer- reviewed journal The Journal of Clinical Investigation--Insight, and builds on data previously disclosed by Patrys. The investigators show that, like the full-size antibody 3E10, Patrys' humanised deoxymab fragment, PAT-DX1 uses the nucleoside transporter protein ENT2 to cross the BBB. Most antibodies are unable to cross either cell membranes or the BBB, which limits their use for certain applications such as treating cancers in the brain and intracellular targeting of therapeutic payloads. Patrys believes
the unique ability of deoxymabs to be transported intact across cell membranes and the BBB using the ENT2 nucleoside transporter is likely to be related to the biology of these particular antibodies rather than provide a general mechanism that could be used for other antibodies. The investigators also demonstrated that PAT-DX1 is able to significantly inhibit the growth of tumours in three different models of cancer once it crosses the BBB. Two different models of glioblastoma (GBM Model 1 and GBM Model 2) were tested and treatment with PAT-DX1 resulted in a 47% (24 days v 17 days, p<0.01) and 25% (73 days v 58 days, p<0.02) improvement in median survival respectively. In both these models, human glioblastoma cells were implanted in the brain tissue of animals which were then treated with PAT-DX1 once tumours had become established in the brain. PAT-DX1 was also tested in a third animal model designed to replicate the metastases of breast cancer into brain tissue. In this model, a human breast cancer cell line that is known to migrate to the brain and establish metastatic tumours was injected into the bloodstream. This model is considered one of the most challenging brain tumour models to treat. The number of tumours established in the brain was significantly reduced (p<0.01) when animals were treated with PAT-DX1 and this reduction in brain cancer metastases resulted in a statistically significant 45% (45 days v 31 days, p<0.002) improvement in median survival. The ability of PAT-DX1 to cross the BBB, localise to both primary and secondary tumours in the brain, and then selectively kill cancer cells by blocking their DNA Damage Repair (DDR) systems highlights the potential for Patrys' deoxymabs to provide much-needed, new therapeutic options for the treatment of cancers located in the brain. Reported Earnings • Feb 21
First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in 1H 2020) First half 2021 results: Net loss: AU$2.00m (loss widened 17% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Announcement • Feb 10
Patrys Limited Successfully Establishes PAT-DX1 Stable Cell Line Patrys Limited announced that it has selected an optimised stable cell line for its lead asset PAT-DX1. This important step allows the company to establish large- scale production of PAT-DX1 deoxymab for final preclinical studies, first-in-man studies, and partnering activities. The establishment of a stable, PAT-DX1-producing cell line by Patrys is the culmination of a manufacturing development and optimisation program that was initiated in mid-2019. The development program included modification of PAT-DX1's protein back-bone to improve its properties for use in human therapeutic applications. Cell lines expressing the modified PAT-DX1 were developed and an extensive selection processes was conducted to identify single, clonal cell lines that produced high yields of high quality PAT-DX1. The final step was to ensure that the cell line was stable and able to deliver reproducible and consistent production of PAT-DX1 protein over time. Over the past months Patrys evaluated six different optimised cell lines and has selected a best performer from these studies. The cell line that has been selected will be stored as a Master Cell Bank (MCB) which will form the basis for all future production of PAT-DX1. The selection of a stable cell line for producing PAT-DX1 means that all future studies undertaken by either Patrys or its partners and collaborators can be based on suitably qualified product, including supporting ongoing research effort being conducted around the globe on this technology. Having a consistent and qualified product means that data can potentially be leveraged from a broad range of studies covering applications such as therapeutics, nanoparticle drug delivery, antibody-drug conjugation and diagnostic imaging agents. Announcement • Oct 05
Patrys Limited Adds Full Human Antibody to Deoxymab Portfolio Patrys Limited announced it has completed initial production and characterisation of PAT-DX3, a full-sized, humanised antibody version of its dimerised antibody fragment PAT-DX1. This full-sized version is likely to have different pharmaceutical properties (pharmacokinetics, half-life and tissue distribution) to PAT-DX1 that may provide opportunities to use it for additional clinical applications. Patrys' lead asset, PAT-DX1 is an engineered version of the mouse lupus antibody 3E10, which has been miniaturised to just contain two copies of the binding domain of 3E10, and further modified to improve its binding properties. PAT-DX1 has been shown to cross the blood brain barrier (BBB), reduce tumour size, and increase survival in multiple animal models of brain cancer, other cancers, and cancer metastases. PAT-DX1 is tumour-agnostic, meaning that it can target many different tumour types in the body, regardless of specific tumour antigens. Initial development and characterisation of PAT-DX3 has confirmed that, like PAT-DX1, it penetrates into cancer cell nuclei and binds to the DNA released from solid tumours. Based on these findings, Patrys expects that PAT-DX3 is likely to show similar efficacy benefits in animal models of cancer. The company intends to undertake testing in these models following pharmacokinetic (PK) studies run in parallel with ongoing PK studies for PAT-DX1. Having both a dimerised antibody fragment (PAT-DX1) and a full-sized, humanised antibody (PAT-DX3) available will provide Patrys with a range of options to exploit the unique characteristics of this antibody for human therapeutic applications. Patrys' existing patent grants and applications cover the use PAT-DX3 as well as PAT-DX1, with patents granted in Europe, Japan, China and the USA. Patrys has granted or pending patents in major jurisdictions where future regulatory approvals and product sales are targeted, and currently has more than 19 patent applications pending across 10 different patent families.